“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of
Producing high quality affordable
and accessible biologics
Lupin Wins Five INDIASTAR 2020 Awards for Excellence in Packaging
Mumbai, October 23, 2020: Pharma major Lupin Limited (Lupin) announced that it has won five ‘INDIASTAR 2020’ awards under the category ‘Excellence in packaging, innovative design and development’ for its derma products – Novegrow, Lupiaqua cream, Novilite cream, Noviglo face wash and Novishine shampoo. The award was conferred by the Indian Institute of Packaging (IIP).
The INDIASTAR Award is a national award for excellence in packaging. A jury of eminent personalities from institutions, government bodies, and industry experts selected the winners from a total of 305 entries. INDIASTAR Awards are duly recognized and endorsed by the Asian Packaging Federation (APF) and the World Packaging Organization (WPO). The winning of IIPs’ INDIASTAR award has opened the doors for winners to compete with their awarded designs for International Awards viz. ASIASTAR and WORLDSTAR.
Commenting on the win Mr. Rajeev Sibal, President – India Region Formulations, Lupin Limited said, “Packaging is a key focus area for us and winning this award is a great honor as it demonstrates our level of commitment to excellence and design while keeping in mind quality, safety and compliance requirements.”
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the 3rd largest pharmaceutical company in the U.S. by prescriptions and 5th in India by global revenues. The Company invests 9.6 % of its revenues on research and development.
Lupin has fifteen manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.
Please visit www.lupin.com for more information.
Follow us on Twitter: www.twitter.com/LupinGlobal | LinkedIn: www.linkedin.com/company/lupin/
For further information or queries please contact –
Head – Investor Relations and Corporate Communications
Tel: +91 22 6640 8237
General Manager – Corporate Communications
Tel: +91 22 6640 2532